
VP of Comms & Partnerships @theA4LI | Biogerontologist | @BuckInstitute & @USCLeonardDavis | Studied ketone bodies @GeriSciDoc |
Joined September 2021
- Tweets570
- Following521
- Followers624
- Likes1.8K
Pinned Tweet
As promised, our agenda is finally announced!!
Today’s the day! The H-SPAN Summit D.C. agenda is officially LIVE!
Check out our incredible lineup of sessions and speakers here: a4li.org/h-span-summit-dc/
Let us know who you’re most excited to see by commenting below!
For the next week, get 20% off a ticket using promo code: HEALTHSPAN
Warmest congratulations to our partners at @Georgetown University and the @BuckInstitute for Research on Aging on securing funding for the BIOmolecular Grammar for protein Aggregation Modulation and Intervention (BIOGAMI) program.
Go Team SEEDS!
Excited to co-lead SEEDS with @Georgetown, supported by @ARPA_H!
This ambitious collaboration aims to predict harmful protein changes linked to disease.
More Monday on the science, researchers and partners!
#BuckInstitute #SEEDS #Livebetterlonger
Brenda Eap, PhD retweeted
Some of the biggest challenges in human health require new ways of thinking.
ARPA-H is looking for the scientists, engineers, physicians, and other technical experts with bold ideas for tackling problems that have remained out of reach through conventional approaches.
Program Managers at ARPA-H have the opportunity to develop and lead ambitious programs, bring together multidisciplinary teams, and move transformative ideas toward real-world health outcomes.
For those with the expertise and a vision for what could be possible, this is an opportunity to turn that vision into action.
ARPA-H is looking for health visionaries.
Deeply technical. Big vision.
Stuck in a role that’s too small for what you want to build?
Bring us your best ideas. Apply to be a Program Manager 🚀
linkedin.com/jobs/view/44661…
Brenda Eap, PhD retweeted
Here's my conversation with @BrackLab on the FDA shift on longevity, and how his PROSPR program will sustain the momentum.
Highly positive panel on longevity trials at ARDD:
Lowell Zeta (chief of staff) says longevity is a priority for the current FDA.
There's now a point person for longevity trial design: Justin Penzenstadler (reviewer on GLP1s).
Steven Kozlowski (chief scientist) working on guidance and tech specs, to be released first half of next year.
Justin recommends the field forma precompetitive consortium for which biomarkers, how to include in trials. And to talk to regulators regularly.
Let’s keep this momentum going!!!
We had an incredibly productive and memorable week on Capitol Hill advocating for A4LI policy proposals! There was strong alignment with our multi-disease therapeutic designation and the importance of @NIH.
We’re excited to keep building on all these amazing conversations!
@BernieSanders @ScottforFlorida @SenateAging @GOPHELP @RepPaulTonko @HouseCommerce @RepGuthrie
NEWS: NIH launches $21 million initiative to improve understanding of sex-specific hormonal biology.
Read the full story ➡️ bit.ly/4h56xWy.
Brenda Eap, PhD retweeted
Good writing and any improvement in this area will go a long way for patients! BUT its central diagnosis (that the science is largely ready and development is now the bottleneck) fits oncology far better than neurodegeneration.🧠
We have not solved the upstream science in Alzheimer's or Parkinson's. We have few (I'd argue, no) therapies for their root causes. These diseases unfold for years or decades before before they become clinically detectable, often through very noisy readouts. So even if you had a potential treatment at hand, it could take a long, looong time before you'd be able to detect an improvement. Faster Ph1 trials are not the (primary) solution for fixing this fundamentally broken feedback loop.
Instead, we'd need better experimental systems, biomarkers and longitudinal data that lets us learn much faster from the bench to patients. Case in point:
Excellent and important piece on clinical trials from @RuxandraTeslo: nytimes.com/2026/09/04/opini…
Brenda Eap, PhD retweeted
For years, critics have labeled Capitol Hill a "gerontocracy." The AP News Congressional Retirements Tracker shows a massive wave of lawmakers heading for the exits this election cycle, while underscoring a broader trend: Congress has steadily aged over the last century. While dozens of members are not seeking reelection to their current seats, many aren't stepping away from public life entirely, opting instead to pursue governorships or Senate seats. As a new generation of leaders steps up, we’ll be watching to see how the demographic landscape of Congress evolves.
Nonetheless, the timing and opportunity for aging biology and longevity biotechnology have never been more ripe. At A4LI, we continue to champion this vision by advocating for policies that accelerate next-generation disease-modifying therapies. By pairing longer lifespans with vibrant healthspans, we ensure everyone has the energy to pursue what they love and the opportunity to pivot careers at any stage of life.
Source: apnews.com/projects/2026-con…
Had a great time chatting with Christina about her journey in science and her current work looking at senescence in the gut in non-human primates at @WakeForest!
This week on A4LI’s Scientist Spotlight, we speak with Dr. Christina Stevens, a fourth-year graduate student in Dr. Kylie Kavanagh's lab at Wake Forest University School of Medicine.
In this episode, we discuss her background in veterinary medicine, how she has applied that to aging research, and what has driven her to pursue a career in academia.
Listen to the full episode here: a4li.org/podcast/scientist-s…
Thank you for the invitation, @agingdoc1!
@theA4LI
IT'S OUT. 🎉
FRONTIERS OF LONGEVITY SCIENCE @SpringerNature
Leading scientists, clinicians, and entrepreneurs on where the field stands, and where it will go.
Science today. Longevity tomorrow. 🚀
Like and repost to help it travel!👇👨⚕️
🔗linkedin.com/posts/agingdoc_…
Brenda Eap, PhD retweeted
What role should public policy play in extending healthy human lifespan?
Our Founder, @dullunlivin, recently joined the @LongevityTech UNLOCKED podcast to discuss why advancing longevity science requires more than scientific breakthroughs. It also requires policies that help bring those breakthroughs to the people who need them.
The conversation explores the growing momentum behind longevity policy, the challenges that remain, and why now is the time to rethink how governments approach healthy aging.
🎥 You can watch the full interview here: youtube.com/watch?v=LCl0oQ5k…
Brenda Eap, PhD retweeted
🧠 Longevity Fact of the Week
12.4 years.
That's the average gap between lifespan and healthspan in the United States.
In other words, the average American spends more than 12 years living with disease or disability before the end of life.
While we have made remarkable progress in helping people live longer, the next challenge is helping people stay healthier for longer.
At A4LI, we have made it our mission to advance policies that accelerate the development of therapies targeting the biology of aging, with the goal of extending not just lifespan, but healthspan as well.
📖 Learn more about the research behind the healthspan gap here: pmc.ncbi.nlm.nih.gov/article…
A great recap if you couldn’t join us last week! Thanks for the opportunity @LongevityTech!
Last week, leaders in academia, longevity biotech, and policymakers came together in Washington, D.C. for our largest H-SPAN Summit to date.
In an article for @LongevityTech, A4LI Vice President of Communications & Partnerships Dr. Brenda Eap reflects on this year’s Summit, from discussions with federal regulators and Members of Congress to the policy priorities that will shape the future of healthy longevity.
You can read the full article here: longevity.technology/news/us…
Brenda Eap, PhD retweeted
Last week, we hosted our biggest and most impactful D.C. Summit yet.
Across three days, we welcomed 250+ attendees, brought together 60+ leaders across the biotech and policymaking space, and facilitated 40+ meetings between longevity stakeholders and Members of Congress. That is why NOW is the time we capitalize on this momentum.
Here’s how you can help:
1️⃣ Back Our Petitions
Pledge your support for our White Papers on Action Network (actionnetwork.org/groups/the…) to help key decision makers understand the importance of longevity science.
2️⃣ Share with your Network
Every signature helps. Help us raise awareness for these initiatives.
Thank you to everyone who attended this year’s Summit, as well as all of you who have supported us over the years. None of this would be possible without you. Together, we can create a world in which everyone can live healthier, longer lives.
Last chance and we mean it!!!!
This is your final invitation to join us at the H-SPAN Summit D.C.
Registration closes this week. If you are serious about the future of longevity, this is the one event you don't want to miss.
Here is a snapshot of the schedule you're about to miss out on:
📅 Day 1: Scientific Breakthroughs
An immersive deep dive into the longevity landscape with insights from @H_L_Clinic, @GenerationLab_ , @X_Therma, @FibroBiologics, @MatterBio, EdenRoc Sciences, Georgetown University Medical Center, and @altos_labs. Plus, an invaluable closing keynote by the honorable Leroy Hood (@PhenomeHealth).
📅 Day 2: Policy & Regulation
We shift the focus entirely to the critical policy levers driving innovation. You’ll hear firsthand from @LMZeta (@US_FDA), @DrAliciaJackson (@ARPA_H), invited speaker @DrOz, @cole4nh (NH House of Representatives), @RepKevinMullin, and the co-chair of the Congressional Longevity Science Caucus, @RepPaulTonko.
Grab your full or single-day ticket before the link closes: a4li.org/h-span-summit-dc/
Brenda Eap, PhD retweeted
Our H-SPAN Summit DC is just around the corner. This year, we’re building on last year’s conversation about cross-agency alignment in funding and regulatory frameworks for longevity.
We are thrilled to close Day 2 of the Summit with a landmark session: “Building the Framework: Policy Levers for Longevity Innovation.” For the first time, senior administration leaders and Members of Congress will join in a singular forum to discuss current federal initiatives and legislative levers that set out to make healthy longevity a national priority and achieve a true "longevity dividend."
Featured speakers for this policy-focused second day include:
•Dr. Mehmet Oz (Tentative), Administrator of the Centers for Medicare & Medicaid Services (CMS)
•Lowell M. Zeta, Acting Chief of Staff and Deputy Commissioner for Strategic Initiatives, U.S. Food and Drug Administration (FDA)
•Dr. Alicia Jackson, Director of the Advanced Research Projects Agency for Health (ARPA-H)
•Congressman Kevin Mullin (CA-14), Representative of the Bay Area Longevity Biotech Ecosystem
•Congressman Jim McGovern (MA-2), Ranking Member of the House Rules Committee and Champion for Nutrition and Healthy Aging Policy
•Congressman Paul Tonko (NY-20), Co-chair of the Congressional Longevity Science Caucus
Brenda Eap, PhD retweeted
Russia has committed $26 billion to longevity science, while China is advancing large-scale stem cell anti-aging trials and expanding aggressive investment in regenerative medicine and longevity biotechnology.
Scientific leadership in longevity is rapidly becoming a defining frontier of global competitiveness. The United States cannot afford to sit on the sidelines.
Join our letter campaign: actionnetwork.org/letters/th…
A positive signal that the longevity ecosystem is gaining the critical visibility it needs from state lawmakers. Excited to get started!
What an unforgettable day! Yesterday marked a monumental win for the geroscience field and the longevity industry. California Senate Resolution 104 passed the floor with a unanimous 35-0 vote!
Joining the presentation on the Senate floor were Dylan Livingston (Founder and CEO of A4LI), Sonia Arrison (Chair of the A4LI Board), Dr. Joon Yun, Remy Gross, and Sean Curran.
We are beyond grateful to @SenJoshBecker and Senator Akilah Weber Pierson for introducing this historic resolution. The Alliance for Longevity Initiatives is excited to get to work and collaborate with LeadingAGE California, California Life Sciences, and the California Chronic Care Coalition on forward-thinking policies that promote aging biology research and public-private collaboration. By integrating longevity strategies into California's public health framework, SR-104 will optimize healthspans while driving significant long-term cost savings for the state!
Brenda Eap, PhD retweeted
HB 1735 has passed the New Hampshire Senate.
The bill was amended during the legislative process, but its passage reflects growing recognition that patients and innovators deserve greater flexibility when pursuing promising longevity therapies.
"The final bill is more limited than we originally hoped for, but it's encouraging to see states like New Hampshire continue engaging with these issues,” said Dylan V. Livingston, Founder and CEO of @theA4LI. “The reality is that patients are looking for more options, and policymakers across the country are increasingly willing to have that conversation."
We are grateful to the many New Hampshire leaders who championed HB 1735, including Governor @KellyAyotte and @NHSpeaker Sherman Packard. We also extend our thanks to the stakeholders, advocates, and volunteers who dedicated their time and energy to supporting the legislation and advancing the conversation around patient access and medical innovation.
This resolution is a positive signal that the longevity ecosystem in CA is gaining critical visibility it needs!
On June 8th, A4LI and a strong representation of academic and biotechnology leaders in longevity will join CA Senator Josh Becker (@SenJoshBecker) as he presents Senate Resolution 104.
SR 104 advocates for a fundamental shift in how California approaches public health and fiscal planning regarding the state's aging population. The resolution encourages state health and aging departments to integrate geroscience into public health programming while fostering collaboration among academia, health plans, and biotechnology firms to pilot innovative longevity medicines and gerotherapeutics.
This is an incredible milestone for California, the leading state for investment, talent, and innovation in the longevity science field!
Resolution Text: legiscan.com/CA/text/SR104/i…
#CA #Healthspan #LongevityScience #A4LI
If you’re interested in attending, please reach out. This is the year to be in DC, and your presence and voice are incredibly important!
The H-SPAN Summit D.C. is only ONE MONTH away!
Join us as we bring together researchers, policymakers, innovators, and advocates working to accelerate progress against age-related diseases and advance the future of medicine.
Registration and Agenda Here: a4li.org/h-span-summit-dc/


































